|
|
|
| Effect of Modified Ginseng Yangrong Decoction on the Expression of Tumor Markers and Th1/Th2 Cytokines in Pelvic Recurrent Cervical Cancer during Concurrent Radiotherapy and Chemotherapy |
| PENG Lei, QIN Hongen, HUANG Huabin, et al |
| The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei Enshi 445000, China |
|
|
|
|
Abstract Objective: To investigate the effect of modified Ginseng Yangrong Decoction on the expression of tumor markers and Th1Th2 cytokines in pelvic recurrent cervical cancer during concurrent radiotherapy and chemotherapy. Methods: 102 patients with recurrent pelvic cervical cancer admitted to our hospital from December 2018 to December 2021 were selected, and divided into the observation group (n=51) and the control group (n=51) in the ratio of 1:1 according to the order of admission single and double numbers. The control group was treated with synchronous radiotherapy, while the observation group was treated with synchronous radiotherapy combined with addition of Ginseng Yangrong Decoction. 21d was set as a cycle for both groups, and 2 cycles of continuous treatment were evaluated. The recent efficacy, KPS score, immune function, tumour markers, Th1/Th2 cytokine changes and toxic side effects of the two groups were compared before and after treatment. Results: The objective remission rate was higher in the observation group than in the control group (70. 95% vs 50. 98%, P<0. 05). The KPS score after treatment was higher in the observation group than in the control group (89. 80±2. 44 vs 73. 92±4. 93, P<0. 05). CD3+, CD4+ and CD4+/CD8+ were higher in the observation group than in the control group after treatment (58. 79±3. 01 vs 50. 81±3. 15, 38. 95±2. 65 vs 31. 29±3. 07, 1. 62±0. 21 vs 1. 04±0. 13, P<0. 05). CEA, CA19-9 and CYFRA21-1 levels were lower in the observation group than in the control group after treatment (83. 42±12. 25 vs 115. 26±20. 39, 18. 94±5. 46 vs 29. 46±6. 28, 4. 67±1. 08 vs 6. 58±1. 25, P<0. 05). The post-treatment levels of IL-2, IL-10, TNF-α and IFN-γ were lower in the observation group than in the control group (12. 26±2. 87 vs 16. 79±2. 54, 18. 29±3. 87 vs 25. 46±3. 34, 15. 47±4. 12 vs 21. 74±2. 95, 19. 98±5. 45 vs 32. 24±6. 65, P< (0. 05). The incidence of toxic side effects in the observation group was lower than that in the control group (11. 76% vs 29. 41%, P<0. 05). Conclusion: Modified Ginseng Yangrong Decoction has obvious curative effect on pelvic recurrent cervical cancer during concurrent radiotherapy and chemotherapy, improves the immune function of patients, reduces the levels of tumor markers CEA, CA19-9 and CYFRA21-1, and regulates the balance of Th1/Th2 cytokines.
|
|
|
|
|
|
[1] Beckmann M,Stuebs FA,Vordermark D,et al.The diagnosis,treatment,and aftercare of cervical carcinoma[J].Dtsch Arztebl Int,2021,118(4):806-812.
[2] 黄东静.外周血肿瘤异常蛋白联合鳞状细胞癌抗原及薄层液基细胞学检查在宫颈癌筛查中的应用[J].川北医学院学报,2021,36(12):1565-1568.
[3] 甘媚,陈敏,梁雷锋,等.阿帕替尼联合同步放化疗治疗化疗耐药局部晚期宫颈癌的临床观察[J].武汉大学学报(医学版),2021,42(6):954-959.
[4] Therasse P,鄢 践,曾益新.实体瘤疗效评定最新指南[J].国外医学肿瘤学分册,2000,27(6):375.
[5] Tomalczyk A,Tomasik B,Fijuth J,et al.Assessment of cervical vascularization density in patients with locally advanced squamous cell cervical carcinoma evaluated in colour doppler and power doppler functions[J].Arch Gynecol Obstet,2022,305(4):955-961.
[6] 张慧慧,王蓓蓓,张献文,等.伴有盆腔淋巴结转移的宫颈癌新辅助化疗联合放化疗临床疗效及预后因素分析[J].中华全科医学,2021,19(11):1823-1826,1839.
[7] 赵明燕.健脾降逆汤联合常规西药对宫颈癌化疗后不良反应的影响[J].新中医,2021,53(23):145-148.
[8] 措毛吉,王烈宏,王榀华,等.人参养荣汤辅助化疗对宫颈癌患者的临床价值[J].中国临床医生杂志,2021,49(2):244-246.
[9] 赵敬,张文帆,杨金豪,等.宫颈癌患者血清肿瘤标志物与内分泌激素的相关性及临床分析[J].临床检验杂志,2021,39(9):679-682.
[10] 凡芳,朱艺欣,左泳泳,等.吉西他滨联合表柔比星对宫颈癌患者的疗效及血清Th1/Th2细胞因子水平的影响[J].检验医学与临床,2021,18(20):2961-2963,2966.
[11] 杨德红.晚期宫颈癌介入与放射治疗的疗效及对Th1/Th2细胞因子水平分析[J].基因组学与应用生物学,2018,37(2):589-595. |
|
|
|
2022, Vol. 28 
